Replimune Group, Inc. (REPL)

Replimune Group Inc. (REPL) is a clinical-stage biotechnology company that develops oncolytic immunotherapies for the treatment of cancer. The company's lead product candidate, RP1, is an intratumoral immune activator that uses a proprietary engineered herpes simplex virus (HSV) to selectively infect and replicate within tumor cells, leading to their destruction and the release of tumor-associated antigens. RP1 is being evaluated in clinical trials for the treatment of multiple types of solid tumors, including melanoma, head and neck cancer, and non-muscle invasive bladder cancer. Replimune is also developing other oncolytic immunotherapies, including RP2, RP3, and RP4, that utilize similar viral vectors and immune modulators.